[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ResoTher Pharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100551839","phase-2-a-study-of-rtp-026-to-assess-safety-tolerability-and-efficacy-in-patients-with-st-elevation-myocardial-infarction-stemi-100551839",false,"NCT06465303","A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)","An Exploratory, Randomised, Double-blind, Multicentre, Placebo-controlled Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)","Inclusion Criteria:\n\n* Informed consent for participation in the study has been obtained prior to initiating any study-specific procedures\n* Men between 18-85 years of age and post-menopausal women up to 85 years of age\n* Acute onset of chest pain of \\\u003C 12 hours duration\n* STEMI as characterized on ECG by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with a minimum of 1 mm concordant ST elevation or 1 mV ST elevation in the limb lead (II, III and aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior acute myocardial infarction (AMI)\n* Eligible for primary PCI\n* NLR in the range of 7-17 at hospital admission. In patients with chest pain lasting \\> 3 - ≤ 6 hours at admission, the NLR should be in the range of 4.8-17 and for patients with chest pain lasting ≤ 3 hours at admission, the NLR should be in the range of 4.8-17, or the neutrophile count should be ≥ 9 x 10E9\u002FL, irrespective of the lymphocyte count. For STEMI patients with an anterior or anterolateral infarction, the NLR should be ≥3.\n\nExclusion Criteria:\n\n* Participation in any other study involving investigational drug(s) during the study and within 4 weeks prior to study entry\n* Previous exposure to RTP-026\n* Time from symptoms onset to primary PCI \\> 12 hours\n* Previous CABG\n* Evidence of active malignant disease\n* Ongoing treatment with immune suppressive compounds\n* Any condition that, in the view of the investigator, would suggest that the patient is unable to comply with the study protocol and procedures\n* Known contraindications to CMR\n* ORBI Risk Score \\> 12","ALL","18 Years","85 Years",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is an exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026.\n\nThe study population will consist of men and women with documented evidence of ST-elevation myocardial infarction (STEMI) referred to primary Percutaneous Coronary Intervention (PCI).",[27],"ST Elevation Myocardial Infarction","RECRUITING","2025-09-16",{"date":31,"type":32},"2025-09-22","ACTUAL",{"date":34,"type":32},"2024-07-16",{"date":36,"type":21},"2025-12-21",{"name":38,"class":39},"ResoTher Pharma","INDUSTRY",""]